Clinical Trial Update: Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating LHC165 alone and with PDR001 in advanced solid tumors; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• LHC165
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Solid Tumors | Phase 1 | Status: TERMINATED